Diagnosing Model Diagnostics

2007/06/14 by M O Karlsson, Mats O. Karlsson, R M Savic +1 · 537 citations
Engineering · Mathematics · Medicine · Pharmacology, Toxicology and Pharmaceutics · #Clinical Laboratory Practices and Quality Control #Clinical pharmacology #Computer science #Engineering #Intensive care medicine #Management science #Medical physics #Medicine #Pharmacogenetics and Drug Metabolism #Pharmacology #Risk analysis (engineering) #Statistical Methods in Clinical Trials

paper · doi:10.1038/sj.clpt.6100241

published in Clinical Pharmacology & Therapeutics 82(1), 17-20 (Wiley)

openalex publication_date 2007/06/14 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/29

Abstract

Conclusions from clinical trial results that are derived from model-based analyses rely on the model adequately describing the underlying system. The traditionally used diagnostics intended to provide information about model adequacy have seldom discussed shortcomings. Without an understanding of the properties of these diagnostics, development and use of new diagnostics, and additional information pertaining to the diagnostics, there is risk that adequate models will be rejected and inadequate models accepted. Thus, a diagnosis of available diagnostics is desirable.

Cited by

• Quantitative Assessment of Population Variability in Hepatic Drug Metabolism Using a Perfused Three-Dimensional Human Liver Microphysiological System
• Population Pharmacokinetic-Pharmacodynamic Analysis of Trastuzumab-Associated Cardiotoxicity
• Pharmacokinetic-Pharmacodynamic Modeling of Antibacterial Drugs
• Population pharmacokinetics of TBAJ‐587 and its main metabolites—Evaluation of different loading dose strategies and early dose selection
• Population pharmacokinetics of levetiracetam in patients diagnosed with refractory epilepsy: A real‐world study
• Pharmacokinetics of Escalating Doses of Oral Psilocybin in Healthy Adults
• Can Population Pharmacokinetics of Antibiotics be Extrapolated? Implications of External Evaluations
• Population Pharmacokinetics and Exposure–Response Modeling of Golimumab in Adults With Moderately to Severely Active Ulcerative Colitis
• Pharmacokinetic–Pharmacodynamic Cutoff Values for Doxycycline in Pigs to Support the Establishment of Clinical Breakpoints for Antimicrobial Susceptibility Testing
• Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions. [europepmc]
• Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis. [europepmc]
• Evaluation of different tests based on observations for external model evaluation of population analyses. [europepmc]
• The role of population PK-PD modelling in paediatric clinical research. [europepmc]
• Marginal increase of sunitinib exposure by grapefruit juice. [europepmc]
• Systematic evaluation of the descriptive and predictive performance of paediatric morphine population models. [europepmc]
• Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. [europepmc]
• Shrinkage in nonlinear mixed-effects population models: quantification, influencing factors, and impact. [europepmc]
• Establishing best practices and guidance in population modeling: an experience with an internal population pharmacokinetic analysis guidance. [europepmc]
• A neonatal amikacin covariate model can be used to predict ontogeny of other drugs eliminated through glomerular filtration in neonates. [europepmc]
• The pharmacokinetics of methadone and its metabolites in neonates, infants, and children. [europepmc]
• Simultaneous pharmacokinetic modeling of gentamicin, tobramycin and vancomycin clearance from neonates to adults: towards a semi-physiological function for maturation in glomerular filtration. [europepmc]
• Population pharmacokinetic analysis of voriconazole and anidulafungin in adult patients with invasive aspergillosis. [europepmc]
• Use of opportunistic clinical data and a population pharmacokinetic model to support dosing of clindamycin for premature infants to adolescents. [europepmc]
• Population pharmacokinetics of bedaquiline (TMC207), a novel antituberculosis drug. [europepmc]
• Covariates of intravenous paracetamol pharmacokinetics in adults. [europepmc]
• Population Pharmacokinetics of Intravenous Paracetamol (Acetaminophen) in Preterm and Term Neonates: Model Development and External Evaluation. [europepmc]
• Pediatric tuberculous meningitis: Model-based approach to determining optimal doses of the anti-tuberculosis drugs rifampin and levofloxacin for children. [europepmc]
• Ocular Drug Distribution After Topical Administration: Population Pharmacokinetic Model in Rabbits. [europepmc]
• Population pharmacokinetics of bevacizumab in cancer patients with external validation. [europepmc]
• A Population Pharmacokinetic Model to Predict the Individual Starting Dose of Tacrolimus Following Pediatric Renal Transplantation. [europepmc]
• Pharmacokinetic-Pharmacodynamic Modeling in Pediatric Drug Development, and the Importance of Standardized Scaling of Clearance. [europepmc]
• A population pharmacokinetic model to predict the individual starting dose of tacrolimus in adult renal transplant recipients. [europepmc]
• Time-Varying Clearance and Impact of Disease State on the Pharmacokinetics of Avelumab in Merkel Cell Carcinoma and Urothelial Carcinoma. [europepmc]
• Population Pharmacokinetic Analysis for Imipenem-Relebactam in Healthy Volunteers and Patients With Bacterial Infections. [europepmc]

Related

• Do We Really Sample Right In Model-Based Diagnosis?
• Learning From What You Don't Observe
• Abductive and Consistency-Based Diagnosis Revisited: a Modeling Perspective
• Evaluating Multi-Turn Multimodal Diagnostic Reasoning on Challenging Real-World Clinical Cases
• Should we test the model assumptions before running a model-based test?